Drug-related problems and potential contributing factors in the management of deep vein thrombosis

详细信息    查看全文

• 作者：Fekede Bekele Daba ; Fisihatsion Tadesse ; Ephrem Engidawork
• 关键词：Deep vein thrombosis ; Drug ; related problems ; Warfarin ; International Normalized Ratio ; Tikur Anbessa Specialized Hospital
• 刊名：BMC Hematology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：1,064 KB
• 参考文献：1.WHO and FIP. Developing Pharmacy Practice: A focus on patient care-Handbook. Geneva: WHO; 2006. The Hague: FIP.
  2.Nickerson A, MacKinnon J, Roberts N, Saulnier L. Drug-Therapy Problems, Inconsistencies and Omissions Identified During a Medication Reconciliation and Seamless Care Service. Healthc Q. 2005;8(Sp):65–72.CrossRef PubMed
  3.Domino FJ. The Five-Minute Clinical Consult 2011. 19th ed. Philadelphia: Lippincott Williams & Wilkins; 2010.
  4.White PJ. Patient factors that influence warfarin dose response. J Pharm Pract. 2010;23(3):194–204.CrossRef PubMed
  5.Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edition. Chest. 2008;133(Suppl):160S–98S.CrossRef PubMed
  6.Karen B. Stockley’s Drug Interactions 2010 Pocket Companion. London: Pharmaceutical press; 2010.
  7.Drug Interactions Checker [http://​www.​drugs.​com/​drug-interactions/​warfarin.​html ]. Accessed 21 June 2013.
  8.Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2012;126(19):2309–16.CrossRef PubMed
  9.Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109(6):481–8.CrossRef PubMed
  10.Banet GA, Waterman AD, Milligan PE, Gatchel SK, Gage BF. Warfarin dose reduction vs. watchful waiting for mild elevations in the international normalized ratio. Chest. 2003;123(2):499–503.CrossRef PubMed
  11.BC Guideline warfarin therapy management [http://​www2.​gov.​bc.​ca/​gov/​content/​health/​practitioner-professional-resources/​bc-guidelines/​warfarin-therapy ]. Accessed 17 July 2013.
  12.American Society of Hematology. 2011 Clinical Practice Guide on Anticoagulant Dosing and Management of Anticoagulant-Associated Bleeding Complications in Adults [http://​www.​hematology.​org/​Clinicians/​Guidelines-Quality/​Quick-Ref/​525.​aspx ]. Accessed 17 July 2013
  13.Wittkowsky AK, Devine EB. Frequency and causes of over-anticoagulation and under-anticoagulation in patients treated with warfarin. Pharmacotherapy. 2004;24(10):1311–6.CrossRef PubMed
  14.Adam J, Ozonoff A, Grant RW, Lori E, Elaine M. Epidemiology of Subtherapeutic Anticoagulation in the United States. Circ Cardiovasc Qual Outcomes. 2009;2:591–7.CrossRef
  15.Warfarin Management - Adult - Ambulatory Clinical Practice Guideline [http://​www.​uwhealth.​org/​files/​uwhealth/​docs/​pdf2/​Ambulatory_​Warfarin_​Guideline.​pdf ]. Accessed 18 July 2013.
  16.Alex S, Ross I, Beng H, Paul A. Consensus Guidelines for Warfarin Therapy. Med J Aust. 2000;172(12):600–5.
  17.Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2_suppl):e152S–84S.PubMedCentral CrossRef PubMed
  18.Njovane XW, Fasinu PS, Rosenkranz B. Comparative evaluation of warfarin utilization in two primary healthcare clinics in the Cape Town area. Cardiovasc J Afr. 2013;24(2):19–23.PubMedCentral CrossRef PubMed
  19.Haines ST, Witt DM, Nutescu EA. Venous thromboembolism. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw Hill Medical; 2008. p. 331–71.
  20.Nutescu A, Shapiro L, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf. 2006;5(3):433–51.CrossRef PubMed
  21.Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001;17(1):1–13.CrossRef PubMed
  
• 作者单位：Fekede Bekele Daba (1)
  Fisihatsion Tadesse (2)
  Ephrem Engidawork (3)
  
  1. Department of Pharmacy, College of Health Sciences, Jimma University, P.O. Box 378, Jimma, Ethiopia
  2. Department of Internal Medicine, Tikur Anbessa specialized hospital, Addis Ababa University, Addis Ababa, Ethiopia
  3. Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia
  
• 刊物主题：Hematology; Angiology; Blood Transfusion Medicine; Cancer Research; Human Genetics; Internal Medicine;
• 出版者：BioMed Central
• ISSN：2052-1839

文摘

Background Patients receiving anticoagulant drugs must be carefully screened for drug-related problems, as such medications, including warfarin have narrow therapeutic ranges and a high potential for complications. Thus, this study was designed to assess drug-related problems in the management of patients with deep vein thrombosis at Tikur Anbessa Specialized Hospital.